Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SynAct Pharma AB ( (SE:SYNACT) ) has shared an update.
SynAct Pharma announced its participation in the upcoming J.P. Morgan Healthcare Conference in San Francisco, where CEO Jeppe Øvlesen will engage with potential partners and investors. The conference presents a significant opportunity for SynAct Pharma to discuss advancements in their resomelagon treatment for rheumatoid arthritis and host-directed therapy for viral infections, potentially impacting their market positioning and stakeholder interests.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm, specializing in resolving inflammation by selectively activating the melanocortin system. The company offers a range of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory responses and help patients achieve immune balance.
Average Trading Volume: 148,182
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.11B
Find detailed analytics on SYNACT stock on TipRanks’ Stock Analysis page.